A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...
EDT Cathie Wood’s ARK Investment buys 35K shares of Recursion Pharmaceuticals (RXRX) todayOptimize Your Investment Research with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback